ArticleScientific reports2026
Antioxidant, antimicrobial, and AMPA receptor modulatory activities of selected medicinal plant extracts reveal multitarget pharmacological potential.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of neurodegenerative and metabolic illnesses worldwide demands innovative treatment approaches. Medicinal plants having known traditional usage, such as Terminalia chebula, Portulaca oleracea, and Artemisia judaica, are abundant in bioactive chemicals. The purpose of this study is to examine their potential as natural remedies by examining their phytochemical composition and multi-target biological activity. Both qualitative and quantitative phytochemical evaluations were performed on the aqueous extracts of the chosen plants. In vitro tests such as DPPH radical scavenging for antioxidant activity, α-amylase and pancreatic lipase inhibition assays for metabolic effects, antimicrobial microdilution testing, and electrophysiological whole-cell patch-clamp recordings to measure modulation of AMPA receptor subunits were used to assess their biological activities. T. chebula showed the greatest quantities of these compounds. T. chebula exhibited the strongest antioxidant activity (DPPH IC₅₀ = 13.64 µg/mL), considerable α-amylase inhibition (IC₅₀ = 60.11 µg/mL), and moderate pancreatic lipase inhibition (IC₅₀ = 468.52 µg/mL) in vitro bioassays, suggesting strong anti-diabetic and anti-obesity capability. The effects of A. judaica and P. oleracea were less pronounced. According to antimicrobial examination, T. chebula and A. judaica shown significant broad-spectrum activity against Candida albicans, Gram-positive, and Gram-negative bacteria. Using whole-cell patch-clamp electrophysiological tests, it was shown that all extracts were antagonists of AMPA receptor subunits (GluA1, GluA2, GluA1/2, GluA2/3), with T. chebula showing the most potent inhibitory action. According to this study, Terminalia chebula is the most effective extract, exhibiting notable multi-target bioactivity against neurological, microbiological, and metabolic targets. The findings support its long-standing application and emphasize its potential as a source of new medicinal compounds. Incorporating these results supports the ongoing investigation of plant extracts in contemporary drug research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.